ArticleiScience2026
Do G4 ligands induce mitochondrial dysfunction without ROS induction.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
G-quadruplex (G4) DNA structures, present in both nuclear and mitochondrial genomes, represent emerging therapeutic targets. Here, we developed and exploited a mitochondrial high-content profiling platform (Mito-HiCP), integrating automated microscopy with quantitative image analysis, to compare the effects of G4 ligands with cisplatin in cancer and normal cells. G4 ligands induce mitochondrial depolarization without reactive oxygen species (ROS) bursts, in contrast to the ROS-associated toxicity of cisplatin. Notably, the G4 ligand 360 A suppresses both mitochondrial and cytosolic ROS levels while retaining tumor selectivity, whereas its non-G4-binding isomer (EDL21) shows no effect, supporting a G4-dependent mechanism. Mechanistically, 360 A reduces mitochondrial DNA copy number, transcription, and electron transport chain protein levels. Using Mito-HiCP, we identify that G4 targeting uncouples mitochondrial membrane potential from ROS production. This reveals a mode of redox regulation that underlies selective anticancer activity and provides a framework to dissect mitochondrial responses and redox regulation across diverse therapeutic perturbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.